William T. Garvey

Endocrinology

1675 University Blvd # 616B
Birmingham, AL 35233

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 214 publications

The association of maternal obesity and gestational diabetes during pregnancy with offspring adiposity and dysmetabolism: the Intergenerational Transmission of Obesity (ITO) study.

The association of maternal obesity and gestational diabetes during pregnancy with offspring adiposity and dysmetabolism: the Intergenerational Transmission of Obesity (ITO) study.

Journal: American journal of perinatology

Published: July 24, 2026

The Association of Maternal Obesity and Gestational Diabetes during Pregnancy with Offspring Adiposity and Dysmetabolism: The Intergenerational Transmission of Obesity (ITO) Study.

The Association of Maternal Obesity and Gestational Diabetes during Pregnancy with Offspring Adiposity and Dysmetabolism: The Intergenerational Transmission of Obesity (ITO) Study.

Journal: American journal of perinatology

Published: July 24, 2026

Shifting the goalposts in obesity drug development.

Shifting the goalposts in obesity drug development.

Journal: Nature medicine

Published: June 23, 2026

Protocol for the CLOCKS study: A 4-arm randomized controlled trial testing the independent and combined effects of 2 chronotherapies-early time-restricted eating and daytime bright light therapy-in adults with type 2 diabetes.

Protocol for the CLOCKS study: A 4-arm randomized controlled trial testing the independent and combined effects of 2 chronotherapies-early time-restricted eating and daytime bright light therapy-in adults with type 2 diabetes.

Journal: Nutrition research (New York, N.Y.)

Published: April 16, 2026

Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.

Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.

Journal: Obesity (Silver Spring, Md.)

Published: April 13, 2026

Weight Loss Improves Predicted 10-Year MACE and Type 2 Diabetes Risk, but Benefits Partially Rebound at 1 Year.

Weight Loss Improves Predicted 10-Year MACE and Type 2 Diabetes Risk, but Benefits Partially Rebound at 1 Year.

Journal: Obesity (Silver Spring, Md.)

Published: March 27, 2026

Oral Semaglutide in Adults with Overweight or Obesity. Reply.

Oral Semaglutide in Adults with Overweight or Obesity. Reply.

Journal: The New England journal of medicine

Published: December 10, 2025

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: December 02, 2025

Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.

Journal: The New England journal of medicine

Published: November 19, 2025

Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.

Journal: The New England journal of medicine

Published: November 19, 2025

Overcoming weight bias in health care systems.

Overcoming weight bias in health care systems.

Journal: The American journal of managed care

Published: September 18, 2025

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.

Journal: The New England journal of medicine

Published: September 11, 2025

Showing 1-12 of 214

Last Updated: 09/26/2026